Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025Presented ...
Cancer researcher Chi Van Dang studies pharmacokinetics—the way the body absorbs, distributes, metabolizes, and excretes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback